Auxilium On a Roll ...
Health Care: Drugs
Acorda Therapeutics Inc. (ACOR: NASDAQ)
$22.07 0.23 | 1.05%
06/04/12 - 02:48 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 21.84 |
| 52 Week High | 33.15 |
| 52 Week Low | 18.36 |
| Avg. Daily Vol. (Mil) | 0.36 |
| Beta (3 year) | 0.99 |
| Share Related Items | |
| Mkt Cap (Mil) | 875.70 |
| Shares Out (Mil) | 40.10 |
| Float (Mil) | 29.48 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.70 |
| Current Ratio | 4.20 |
| LT Debt/ Equity | 0.02 |
| Total Debt / Equity | 0.03 |
| Valuation Ratios | |
| Price Earnings | 22.80 |
| Price/Sales | 2.90 |
| Price/Book | 4.00 |
| Price/Cash Flow | 17.50 |
| Per Share Data | |
| Earnings | 0.96 |
| Sales | 7.54 |
| Book Value | 5.46 |
| Cash Flow | 1.25 |
| Business Summary | |
|---|---|
| Acorda Therapeutics, Inc. is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and disorders of the central nervous system. | |
| General Information | |
| 15 Skyline Drive
Hawthorne, NY 10532 |
|
| www.acorda.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 328 | |
| CEO: Ron Cohen,M.D. | |
| Short Interest | |
| Current Month (Mil) | 2.52 |
| Previous Month (Mil) | 2.26 |
| Short Interest Ratio (Days) | 7.00 |
| Management Effectiveness | |
| Return on Equity | 17.90 |
| Return on Assets | 10.10 |
| Return on Investments | 17.50 |
| Profitability | |
| Gross Margin | 81.50 |
| EBIT Margin | 14.60 |
| Profit Margin | 12.90 |
Portfolios with ACOR
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor13 Biotech Stocks Bought an...
- Contributor5 Biotech Drug-Launch Stock...
- Usergrandpicks
- UserPART 1 JPMorgan 28th Annual...
- ContributorBarron's Research Reports 3...
- UserUndervalued Biotech's
- UserPART 1 JPMorgan 27th Annual...
- UserFerrengi Holdings
Latest ACOR Headlines from TheStreet
- FDA More Problematic Than Obamacare, Says Acorda CEO
04.24.12 | 06:04 am - BIO CEO Confab Live Blog: Day 2 02.14.12 | 10:02 am
- BIO CEO Conference Live Blog 02.13.12 | 01:02 pm
- 8 Stocks Rising on Huge Volume 01.05.12 | 02:01 pm
- Acorda Rises On Unusually High Volume (ACOR) 11.04.11 | 04:11 pm
- Acorda Stock Hits New 52-Week Low (ACOR) 09.29.11 | 01:09 pm
- SAC Upped Dendreon Exposure Before Blowup 08.15.11 | 05:08 pm
- 5 Biotech Drug-Launch Stocks to Watch 07.18.11 | 09:07 am
- Acorda Stock Gaps Up On Today's Open (ACOR) 05.20.11 | 09:05 am
- European Regulators Approve New Drugs 05.20.11 | 07:05 am
Press Releases for ACOR
- Robbins Umeda LLP Announces An Investigation Of Acorda Therapeutics, Inc. - Business Wire 06.04.12 | 11:06 am
- New Research Presented At 4th Collaborative Meeting Of CMSC And ACTRIMS Expands Understanding Of MS-Related Walking Impairment And Clinical Usage Of AMPYRA® - Business Wire 05.31.12 | 06:05 am
- Acorda Therapeutics Launches First-Ever Online Talk Show Focusing On Walking Problems In Multiple Sclerosis - Business Wire 05.30.12 | 07:05 am
- Acorda Therapeutics Recognized As One Of The Best Places To Work In New York State For Second Consecutive Year - Business Wire 04.30.12 | 07:04 am
- Acorda Therapeutics Presents AMPYRA® Long-Term Safety And Efficacy Data At 64th American Academy Of Neurology Annual Meeting - Business Wire 04.25.12 | 07:04 am
- Acorda Therapeutics Named One Of The 100 Most Trustworthy Companies By Forbes - Business Wire 04.12.12 | 07:04 am
- Acorda Therapeutics To Provide Pipeline Update At Upcoming R&D Day - Business Wire 04.10.12 | 07:04 am
- Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment With Ampyra® (Dalfampridine) Of Walking Problems In Patients With Multiple Sclerosis - Business Wire 04.02.12 | 08:04 am
- Acorda Therapeutics To Present At The Cowen & Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 07:02 am
- Acorda Therapeutics To Present At 2012 RBC Capital Markets' Global Healthcare Conference - Business Wire 02.22.12 | 06:02 am
Partner Headlines for ACOR
- Revenues Climb at Acorda - Analyst Blog - Zacks 05.04.12 | 06:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 04.17.12 | 09:04 am
- Biogen's Fampyra Launched in Canada - Analyst Blog - Zacks 04.13.12 | 06:04 pm
- 4 Compelling Alternatives To Vertex Pharma - Seeking Alpha 02.23.12 | 08:02 am
- 5 Stocks Ripe For A Takeover - Seeking Alpha 10.28.11 | 05:10 pm
- Notable Call Options Activity in Acorda Therapeutics - Benzinga 10.13.11 | 01:10 pm
- Company News for October 6, 2011 - Corporate Summary - Zacks 10.06.11 | 10:10 am
- 7 Possible Biotech Takeover Targets - Seeking Alpha 09.18.11 | 08:09 am
- 5 Biotech Takeover / LBO Targets With Bullish Short Trends - Seeking Alpha 07.15.11 | 07:07 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 07.12.11 | 09:07 am
